Evidence map›Paper›PMID 40607157›Full record

ReviewDiabetology international2025

Regulation of glucose metabolism by incretins: implications for treatment of type 2 diabetes.

Rie Saito, Norio Harada

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Rie SaitoDepartment of Endocrinology and Metabolism, School of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho Yoshida-gun, Fukui, 910-1193 Japan.
Norio HaradaDepartment of Endocrinology and Metabolism, School of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho Yoshida-gun, Fukui, 910-1193 Japan.ORCID 0000-0001-8720-1013

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal hormones that potentiate insulin secretion from pancreatic β-cells are called incretins. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the major incretins. Incretin-mediated stimulation of insulin secretion (incretin effect) plays an important role in lowering postprandial blood-glucose levels. Incretin effect is reduced under diabetic condition. Several mechanisms have been reported for the reduction of incretin effect. Incretin-related drugs are used worldwide for the treatment of type 2 diabetes. In addition, several new incretin-related drugs have been developed and are expected to be available in clinical practice.

Indexed as

GIPGLP-1IncretinIncretin effectInsulin secretion

Identifiers

PMID40607157
PMCPMC12209163

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.